Katja Elina Välimäki — University of Helsinki

Phone+358504160546, +358294125885
Emailkatja.valimakihelsinkifi

PL 20 (Tukholmankatu 8)
00014
Finland

Research activity per year

If you made any changes in Pure these will be visible here soon.

10 Article
2 Meeting Abstract

Drug response profiles in patient-derived cancer cells across histological subtypes of ovarian cancer: real-time therapy tailoring for a patient with low-grade serous carcinoma
Murumägi, A., Ungureanu, D., Khan, S., Arjama, M., Välimäki, K., Ianevski, A., Ianevski, P., Bergstrom, R., Dini, A., Kanerva, A., Koivisto-Korander, R., Tapper, J., Lassus, H., Loukovaara, M., Mägi, A., Hirasawa, A., Aoki, D., Pietiäinen, V., Pellinen, T., Butzow, R., & 2 othersAittokallio, T. & Kallioniemi, O., 16 Feb 2023, In: British Journal of Cancer. 128, 4, p. 678–690 13 p.
Research output: Contribution to journal › Article › Scientific › peer-review

Open Access
File
Fibroblast subsets in non-small cell lung cancer: Associations with survival, mutations, and immune features
Pellinen, T., Paavolainen, L., Martin-Bernabe, A., Araujo, R. P., Strell, C., Mezheyeuski, A., Backman, M., La Fleur, L., Brück, O., Sjolund, J., Holmberg, E., Välimäki, K., Brunnström, H., Botling, J., Moreno-Ruiz, P., Kallioniemi, O., Micke, P. & Östman, A., 10 Jan 2023, In: Journal of the National Cancer Institute. 115, 1, p. 71–82 12 p.
Research output: Contribution to journal › Article › Scientific › peer-review

Open Access
File
ROR1-STAT3 signaling contributes to ovarian cancer intra-tumor heterogeneity
Piki, E., Dini, A., Raivola, J., Salokas, K., Zhang, K., Varjosalo, M., Pellinen, T., Välimäki, K., Veskimäe, K. T., Staff, S., Hautaniemi, S., Murumägi, A. & Ungureanu, D., 3 Jul 2023, In: Cell death discovery . 9, 1, 10 p., 222.
Research output: Contribution to journal › Article › Scientific › peer-review

Open Access
File
E-cadherin is a robust prognostic biomarker in colorectal cancer and low expression is associated with sensitivity to inhibitors of topoisomerase, aurora, and HSP90 in preclinical models
Bruun, J., Eide, P. W., Bergsland, C. H., Bruck, O., Svindland, A., Arjama, M., Välimäki, K., Bjornslett, M., Guren, M. G., Kallioniemi, O., Nesbakken, A., Lothe, R. A. & Pellinen, T., 2022, In: Molecular oncology. 16, 12, p. 2312-2329 18 p.
Research output: Contribution to journal › Article › Scientific › peer-review

Open Access
File
High-throughput ex vivo drug testing identifies potential drugs and drug combinations for NRAS-positive malignant melanoma
Kohtamäki, L., Arjama, M., Mäkelä, S., Ianevski, P., Välimäki, K., Juteau, S., Ilmonen, S., Ungureanu, D., Kallioniemi, O., Murumägi, A. & Hernberg, M., Jan 2022, In: Translational oncology. 15, 1, 11 p., 101290.
Research output: Contribution to journal › Article › Scientific › peer-review

Open Access
File

1 Active

Syöpäs 2023-25 Pellinen
Arjama, M. A., Säilä, J. S., Välimäki, K. E. & Pellinen, T.
Syöpäsäätiö sr Cancerstiftelsen sr
01/01/2023 → 31/12/2024
Project: Foundations (Private Foundations, Non-Profit Foundations, Charitable Trusts)